Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-09-25
2007-09-25
Qian, Celine (Department: 1636)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S070100, C530S350000
Reexamination Certificate
active
10493393
ABSTRACT:
The present invention relates to human, rat and mouse stem cell-derived neuron survival factor polypeptides (SDNSF), a process for producing them, cDNA encoding SDNSF, a vector comprising the cDNA, host cells transformed by the vector, an antibody against SDNSF, pharmaceutical compositions containing SDNSF or the antibody, a method of assaying SDNSF, a reagent for assaying SDNSF, and a screening method using SDNSF. The polypeptides are effective in the survival of nerve cells and, therefore, efficacious in treating injury to the central nerve system caused by brain infarction, brain hemorrhage, spinal cord injury, etc.
REFERENCES:
patent: 4677099 (1987-06-01), Shinitzky et al.
patent: 6605592 (2003-08-01), Ni et al.
patent: 2005/0064543 (2005-03-01), Tang et al.
patent: 99/18204 (1999-04-01), None
patent: 01/21658 (2001-03-01), None
Deka et al. Repetitive nucleotide sequence insertions into a novel calmodulin-related gene and its processed pseudogene Gene, vol. 71, No. 1, pp. 123-134, Nov. 1988.
Zhang et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transplant complex. Nature Genetics, vol. 34, No. 2, pp. 220-225, Jun. 2003.
Uniprot entry Q8NI22, printed on Jun. 27, 2005.
Dirnagle et al. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. vol. 22, No. 9, pp. 391-397, Sep. 1999.
Agrawal et al. In situ stem cell therapy: novel targets, familiar challenges. Trends Biotechnol. vol. 23, No. 2, pp. 78-83, Feb. 2005.
Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. vol. 30, No. 12, pp. 2752-2758, Dec. 1999.
Lees. Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke. vol. 33, No. 1, pp. 308-309, Jan. 2002.
Maurelli et al. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma ‘anandamide amidohydrolase’. FEBS Letters, vol. 377, pp. 82-86, 1995.
UniprotKB Entry: Q8K5B2 for Accession No. Q8K5B2, Sep. 5, 2006.
Tiger et al. Pharmacological properties of rat brain fatty acid amidohydrolase in different subceullular fractions using palmitoylethanolamide as substrate. Biochemical Pharmacology, vol. 59, pp. 647-653, 2000.
UniprotKB Entry: Q8K5B3 for Accession No. Q8K5B3, Sep. 5, 2006.
Philippe Taupin et al., “FGF-2-Responsive Neural Stem Cell Proliferation Requires CCg, A Novel Autocrine/Paracrine Cofactor”, Neuron (2000) vol. 28, pp. 385-397.
D. D. Sabatini et al., “The Signal Sequence Trap Method”, Methods in Enzymology (1999) vol. 303, pp. 479-495.
Hiroki Toda et al., “Stem Cell-derived Neural Stem/Progenitor Cell Supporting Factor Is an Autocrine/Paracrine Survival Factor for Adult Neural Stem/Progenitor Cells”, The Journal of Biological Chemistry (2003), vol. 278, No. 37, pp. 35491-35499.
Supplementary European Search Report dated Dec. 9, 2004.
Honjo Tasuku
Takahashi Jun
Tashiro Kei
Toda Hiroki
Dunston Jennifer
Honjo Tasuku
Ono Pharmaceuticals Co. Ltd.
Qian Celine
Sughrue Mion Pllc.
LandOfFree
Human and mammalian stem cell-derived neuron survival factors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human and mammalian stem cell-derived neuron survival factors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human and mammalian stem cell-derived neuron survival factors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803115